Protein kinase inhibitor sensitivity mechanism reconstruction

A clinical-stage oncology biotech developing a next-generation targeted cancer immunotherapy wanted to validate the mechanism of action of its lead kinase inhibitor, support combination-therapy strategies, and identify resistance biomarkers for patient stratification. Clarivate ran an integrated multi-omics analysis of kinase activity and phospho-proteomics in drug-treated cancer cell lines, used MetaBase-curated signaling pathways to reconstruct drug-response subnetworks, and built a causal network mapping upstream regulators and pathways mediating drug sensitivity/resistance. The in-silico approach confirmed the asset's primary target as the principal driver of treatment effect, supporting MoA validation, and identified key regulators and sensitivity mechanisms that informed patient-stratification strategy and highlighted intervention points for combination therapies to overcome resistance.

The customer is anonymised in Clarivate’s own case study — not withheld by us.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.